Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.
about
Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasisNew Oral Therapies for Psoriasis: A Comprehensive ReviewManagement of cardiovascular disease in patients with psoriasis.Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body WeightTreatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.Efficacy of Immunobiologic and Small Molecule Inhibitor Drugs for Psoriasis: A Systematic Review and Meta-Analysis of Randomized Clinical TrialsPregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokinesOral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study.Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study.Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis.Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis.Novel systemic therapies for the treatment of psoriasis.Secukinumab (AIN-457) for the treatment of Psoriasis.The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations.JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.JAK inhibition in inflammatory bowel disease.New therapies for psoriasis and psoriatic arthritis.Quantitative Evaluations of Time-Course and Treatment Effects of Systemic Agents for Psoriasis: A Model-Based Meta-Analysis.A Review of Psoriasis, Therapies, and Suicide.Tofacitinib for the treatment of psoriasis.Recent Advances in Small Molecule and Biological Therapeutic Approaches in the Treatment of Psoriasis.Managing Scalp Psoriasis: An Evidence-Based Review.Targeted therapies: what they teach us about the pathogenesis of psoriasis and psoriatic arthritis.JAK inhibitors in dermatology: The promise of a new drug class.Apremilast for the management of moderate to severe plaque psoriasis.Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study.Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial.New insight into the pathogenesis of nail psoriasis and overview of treatment strategies.Transforming Mutations of Jak3 (A573V and M511I) Show Differential Sensitivity to Selective Jak3 Inhibitors.Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study.Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.Newer treatments of psoriasis regarding IL-23 inhibitors, phosphodiesterase 4 inhibitors, and Janus kinase inhibitors.Tofacitinib: A New Oral Therapy for Psoriasis.Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups.Psoriasis: A STAT3-Centric View.JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.Advances in treating psoriasis in the elderly with small molecule inhibitors.
P2860
Q26765028-F46C1D0A-0B00-4D2E-887B-BCDAF99EC497Q28071475-232D0733-6A4E-4E5C-8293-4D311EF0F827Q30250278-9F5F5A44-24B0-468E-A3BF-24409CEFF6FEQ33729774-DF60FAB5-90A6-41A6-8BED-924384A5B86AQ36157003-9B63D2A2-920F-4F21-9879-B86A22742A9AQ36190962-4E74149D-F955-4889-95A0-74E22BAA98AEQ37067150-39245CBE-B7AD-4B21-BDC5-5B1C1D21A3D5Q37148745-FFFFDC17-C752-4AC7-9879-57E241EAD442Q37345488-DEE39BC6-7452-4EE6-91D4-57C27854C223Q37412781-644F85C5-6933-43C6-978D-0E61C96909B0Q37484842-E20D09A9-5D53-4AE2-9B14-C63A612DEFE1Q37604501-6049CBF3-C8D2-4121-9BFE-316E3434441BQ37631750-33C1B178-2EA8-405D-96A3-3E3E6A6CD6E4Q38628193-2F0935CD-3486-44CD-AE1E-40B4CC44F7D2Q38662868-863F9616-4AE2-4C78-97C1-4B60CBAC0188Q38687571-F12BF6A1-9F3E-4A35-8F0F-68D919D755CEQ38751230-674B72F3-54D8-4AD2-8DF4-464436DC2694Q38761142-072C18F4-6CC2-4F82-9DDC-D2FD7A267644Q38792080-CBAC7825-979C-4699-AE30-F526C67D0997Q38799023-988316AB-C93B-46D8-BC95-695A9EC61542Q38840271-869F8138-052E-43B3-81F2-9955601F4B4DQ38856883-4EDFB2E1-3983-4321-BE1A-1404D68AB2F7Q38895147-58557F00-4CA3-44C3-BBCE-F04672BFEBDAQ38960080-62350351-9473-4E0A-82C4-BAF4346EFC74Q38969036-88DAD855-36A3-4778-9243-DAB381DB9310Q39111032-630C66C9-196F-4CE7-8FC0-5B8EF517951CQ39170240-2E6820BD-A6F5-445A-81EB-C2F2721FEB7EQ39935531-C34B026A-15D3-4E1D-967B-14A45D846BFAQ40132474-ED4191FA-0C5B-463D-BE08-D0FDD3DBB8FBQ41633453-D6290F21-430E-4FDC-B9DD-C52D8B2DD1E9Q42378681-F2E01CD5-0D91-46AD-8155-1D19AAB136C7Q47100492-DA2C7B93-A955-4E50-A88A-16B4E70C93FBQ47260366-E274EF87-0A32-4694-9552-DCF1203842C4Q47349992-D42A3405-2495-4149-84F8-A3486E49A932Q47585528-1146EC90-C05C-4374-B90A-D94103B51108Q47623085-04ADFCA2-4997-4302-BC82-549653D84A05Q48170767-E2F30D52-9028-4068-8EFB-DFB8BC1A575DQ48278607-A528C97F-B20E-4167-A556-80E4A84BD570Q48556502-704A58A7-543B-46C6-899F-27387DD9C7E9Q49679446-CEAD5321-5C8A-44EA-922C-4C75C43D9F86
P2860
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Tofacitinib, an oral Janus kin ...... -controlled, phase III trials.
@ast
Tofacitinib, an oral Janus kin ...... -controlled, phase III trials.
@en
Tofacitinib, an oral Janus kin ...... -controlled, phase III trials.
@nl
type
label
Tofacitinib, an oral Janus kin ...... -controlled, phase III trials.
@ast
Tofacitinib, an oral Janus kin ...... -controlled, phase III trials.
@en
Tofacitinib, an oral Janus kin ...... -controlled, phase III trials.
@nl
prefLabel
Tofacitinib, an oral Janus kin ...... -controlled, phase III trials.
@ast
Tofacitinib, an oral Janus kin ...... -controlled, phase III trials.
@en
Tofacitinib, an oral Janus kin ...... -controlled, phase III trials.
@nl
P2093
P356
P1476
Tofacitinib, an oral Janus kin ...... -controlled, phase III trials.
@en
P2093
A B Gottlieb
M A Menter
M Buonanno
OPT Pivotal 1 and OPT Pivotal 2 investigators
P304
P356
10.1111/BJD.14018
P407
P50
P577
2015-07-07T00:00:00Z